Nav1.4 is the principal adult skeletal-muscle voltage-gated sodium channel encoded by SCN4A. It is the dominant fast inward current source that converts endplate depolarization into propagated muscle action potentials.[1][2] In channel-physiology terms, Nav1.4 determines how easily a muscle fiber fires, how quickly it recovers from inactivation, and how strongly repeated stimulation is translated into force generation.[2:1][3]
Although Nav1.4 is not a primary Alzheimer/Parkinson disease gene, it is mechanistically relevant to NeuroWiki because neuromuscular excitability, membrane-channel dysfunction, and ion-homeostasis failure are recurring themes across neurodegenerative syndromes.[3:1][4]
Nav1.4 follows the canonical sodium-channel design: four homologous domains (DI-DIV), each with six transmembrane segments, with pore-forming S5-S6 loops and voltage-sensing S4 helices.[1:1][2:2] Fast inactivation depends on coordinated conformational transitions centered on the DIII-DIV linker and pore domain, and many pathogenic variants shift activation/inactivation balance toward persistent inward sodium current.[2:3][3:2]
From a systems perspective, the clinically important variable is not only peak current amplitude but also gating kinetics: small defects in inactivation or recovery can convert normal contraction into myotonia, episodic weakness, or paradoxical stiffness under stressors such as exercise, cooling, or potassium load.[2:4][5]
Under normal conditions, Nav1.4:
Because sodium-current reserve is finite, partial loss of function can reduce excitability (periodic paralysis phenotypes), while gain-of-function defects can produce membrane hyperexcitability and after-discharges (myotonia spectrum disorders).[2:7][5:1]
The strongest evidence base links Nav1.4 dysfunction to non-dystrophic myotonias and periodic paralysis syndromes.[2:8][3:4][5:2]
Consensus management frameworks now combine genotype context, trigger profiling, and symptom-directed membrane-stabilizing strategies.[5:3]
Nav1.4 itself is not a canonical AD/PD risk driver. Its translational value for this wiki is methodological:
Current treatment logic in Nav1.4 channelopathies emphasizes symptom control and trigger modulation.[2:11][5:4]
This genotype-to-therapy mapping is a useful template for other channel-centered therapeutic pages.
Catterall WA. Voltage-gated sodium channels at 60: structure, function and pathophysiology. The Journal of Physiology. 2012. ↩︎ ↩︎ ↩︎
Desaphy JF, Camerino DC, George AL Jr, Conte Camerino D. Skeletal muscle sodium channelopathies. Current Opinion in Neurology. 2015. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Cannon SC. Sodium Channelopathies of Skeletal Muscle. Handbook of Experimental Pharmacology. 2018. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
de Lera Ruiz M, Kraus RL. Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications. Journal of Medicinal Chemistry. 2015. ↩︎ ↩︎
Stunnenberg BC, LoRusso S, Arnold WD, et al. Guidelines on clinical presentation and management of nondystrophic myotonias. Muscle & Nerve. 2020. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Elia N, Palmio J, Udd B, et al. New Challenges Resulting From the Loss of Function of Na(v)1.4 in Neuromuscular Diseases. Frontiers in Pharmacology. 2021. ↩︎